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Cardiac resynchronization therapy (CRT) has proved to be
beneﬁcial for patients with moderate-to-severe heart failure
with prolonged QRS duration and reduced left ventricular
ejection fraction. Placement of a left ventricular (LV) lead in
an adequate location has been shown to increase response to
CRT1,2 but can become a complex procedure because of
challenging coronary vein anatomies. We report the case of a
patient in whom a novel LV lead was successfully implanted
in a very-large-diameter coronary vein.Case report
A 75-year-old man was diagnosed with heart failure
symptoms (New York Heart Association [NYHA] class
III) due to postmyocardial infarction dilated cardiomyop-
athy. Based on ejection fraction of 30%, left bundle branch
block, QRS duration of 160 ms, and permanent atrial
ﬁbrillation, CRT implantation was recommended.
Echocardiography with velocity vector imaging, speckle
tracking, and strain rate measurements was performed to
identify the region of latest mechanical activation and the
optimal location for LV lead placement. Echocardiographic
measurements revealed signiﬁcant interventricular and intra-
ventricular delay, with the mid to basal lateral wall being
most delayed. Therefore, this location was chosen as the
target for the LV lead.
A pocket was made in the left pectoral region. The
coronary sinus was cannulated using a diagnostic catheter
Medtronic Torqr 4F6F JSN inside together with an Attain
Commandþ Surevalve 6250VI-MB2 delivery system.KEYWORDS Left heart; Active ﬁxation; Coronary sinus; Targeted lead
placement
ABBREVIATIONS CRT ¼ cardiac resynchronization therapy; LV ¼ left
ventricle; NYHA ¼ New York Heart Association
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).Venography of the coronary venous anatomy was per-
formed using a Medtronic Attain Balloon 6215-80 cm to
determine whether a suitable target vein for LV lead place-
ment was available. The venogram revealed only 1 very-
large-diameter coronary vein that did not have any side
branches (Figure 1). The large-diameter vein was measured,
and the vein size in the targeted location ranged from 6.44
mm (19.3Fr) to 5.56 mm (16.7Fr).
We discussed all the potential options and decided to
place the Attain Stability LV lead (model 20066, Med-
tronic, Maastricht, the Netherlands) into the targeted
location. This new LV lead, CE-marked and recently
commercially available (outside the United States), is the
ﬁrst for use in the coronary sinus branches and has an
active ﬁxation mechanism based on a screw (Figure 2).
The lead is a 4Fr bipolar, over-the-wire, steroid-eluting,
active ﬁxation lead that is a derivative of the market-
released Attain Ability model 4196 lead. Like all other
market-released LV leads, it can be delivered using a
guidewire or stylet, and its size is compatible with
subselection catheters for anatomies that have acute-
angle side branches. The model 20066 LV lead has a
small exposed side helix, located 36 mm proximal to the
tip, that enables the implanter to securely ﬁxate the lead to
the vein wall by rotating the lead body. A key design
feature is a mechanical stop at the base of the helix that
prevents overtorquing and entrapment of the venous wall
tissue. The helix is designed to avoid becoming caught on
any component of the delivery sheath or the vein wall
during insertion or retraction. It straightens when traction
force must be applied during lead extraction. In a multi-
center clinical study in which this lead was investigated
for its safety and performance, 1 patient had a lead
extraction at 12 months, with no issues during the study.3
The lead was delivered to the target location using an
Attain hybrid guidewire. We advanced the guidewire as
distal as possible and were able to bow the helix toward the
vessel wall. Despite the extreme diameter of the vein, we
were able to easily rotate the lead body and screw the helix
into the endothelial wall on our ﬁrst attempt. Thepen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.01.006
KEY TEACHING POINTS
 The response to cardiac resynchronization therapy
(CRT) is determined by the position of the left
ventricular lead.
 Before the introduction of the Attain Stability, a
novel left ventricular active ﬁxation lead, CRT was a
compromise between cardiac veins anatomy,
capture threshold, and phrenic nerve stimulation.
With the Attain Stability, now it is only important
to identify the target area. It is very easy to reach
the area, provides optimal stability and good
pacing capture thresholds, and avoids phrenic
nerve stimulation.
 In this case, the Attain Stability lead was the only
possible lead for optimal lead placement.
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(Figure 3).
Electrical measurements revealed a normal capture
threshold of 0.7 V at 0.5-ms pulse width in a bipolar
conﬁguration, impedance of 800 Ω, and R wave of 9 mV.
At 2-month follow-up, the electrical parameters were
normal (threshold 0.75 V at 0.5 ms and impedance 850
Ω), and electrode position had remained stable (Table 1).
After 4 months (November 2014), the patient had clin-
ically improved from NYHA class III to class I–II despite
a suboptimal percentage of pacing. Ejection fraction
improved from 30% to 38%, with a consensual reductionFigure 1 Cardiac venography showing onof LV volumes from 180 to 160 mL. QRS duration
decreased from 160 to 130 ms. Permanent atrial ﬁbrillation
was still present, as was moderate mitral regurgitation.
Considering the patient’s clinical and echocardiographic
improvement, atrioventricular nodal ablation was not planned
per our usual protocol. The dose of beta-blocker was
increased.
Discussion
Currently no alternative leads labeled for use in the LV are
available on the market that would have allowed us to pace
in the predetermined targeted location in this unusual
anatomy (very large target vein). Wedging a quadripolar
lead would have been an option, but because of the very
large diameter of the vein we did not believe that any
shape of lead would have been stable in the proximal/
medium segment of the vein, and the most proximal
electrode likely would not have been able to pace basal
enough due to poor contact with the myocardium. Using
an Attain Starﬁx (Medtronic), which contains an extend-
able lobe active ﬁxation mechanism, would have an
option, but in our opinion this lead would not have been
stable in this vein because of the soft lobes. Moreover, the
Starﬁx lead is a unipolar lead. There have been some
reports of stenting leads into place,4 but because of the
extreme diameter of this vein and discomfort with using
stents on LV leads, we did not believe this to be an
acceptable option. Referring the patient for epicardial
lead placement also would have been a less appropriate
option given the cost of an additional procedure and the
challenges in placing the lead at the site of latestly a very-large-diameter coronary vein.
Figure 3 Final left ventricular lead position ﬁxated to the main coronary sinus (left: right anterior oblique projection; right: left anterior oblique projection).
Inset, left: Close-up of the helix.
Table 1 Electrical parameters at implant and at 2-month follow-up
At implant At 2-month follow-up
R-wave amplitude 9 mV NA (9 mV manual)
Pacing threshold (at 0.5 ms) 0.7 V invasive, 0.75 V with programmer 0.75 V
Pacing impedance 800 Ω 850 Ω
Figure 2 Model 20066 left ventricular lead with a close-up of the helix ﬁxation mechanism.
Heart Rhythm Case Reports, Vol 1, No 3, May 2015132mechanical activation. This novel lead made it possible to
achieve easy and stable placement in the targeted location
despite the large diameter of the vein.
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